Latest KFF Health News Stories
Are Public Health Ads Worth the Price? Not if They’re All About Fear
Public service announcements about drug use or other public health problems often fall short, public health marketing experts say, because they incite people’s worst fears rather than giving people solutions.
Biden’s First Order of Business May Be to Undo Trump’s Policies, but It Won’t Be Easy
President Donald Trump made substantial changes to the nation’s health care system using executive branch authority. But reversing policies that Democrats oppose would take time and personnel resources, competing with other priorities of the new administration.
Many Health Plans Now Must Cover Full Cost of Expensive HIV Prevention Drugs
Most private insurance will be required to cover drugs, like Truvada, that offer protection against HIV infection, without making plan members share the cost.
Seniors Face Crushing Drug Costs as Congress Stalls on Capping Medicare Out-Of-Pockets
While many private insurers cap what members pay in health costs, Medicare does not. Democrats and Republicans in Congress have proposed annual limits ranging from $2,000 to $3,100. But there’s disagreement about how to pay for that cost cap.
Durante la inscripción de ACA, elegir un plan genera nuevas complicaciones de COVID
Las personas que compran su propio seguro médico enfrentan desafíos, en particular los pacientes que tuvieron COVID-19 y que presentan problemas de salud persistentes.
During ACA Open Enrollment, Picking a Plan Invites New COVID Complications
COVID-19’s “long haulers” — patients with lingering effects of the disease — have joined the ranks of Americans with preexisting conditions. For those shopping for health coverage on the individual market, here’s help navigating an uncharted insurance landscape.
Surprise Federal Drug Rule Directs Insurers to Reveal What They Pay for Prescription Drugs
A provision the Trump administration tucked into its final rule on health plan price transparency requires telling consumers what they will pay out-of-pocket for drugs and showing them what the plan paid.
Progressive Group Highlights Trump, Tillis Weakness on Insulin Price Tags
The progressive Change Now PAC launched a campaign ad, which also circulated on Facebook, criticizing President Donald Trump and Sen. Thom Tillis (R-N.C.) for not “fighting” for people with diabetes who struggle with the high cost of insulin.
Not Pandemic-Proof: Insulin Copay Caps Fall Short, Fueling Underground Exchanges
Although sharing prescription medicines is illegal, many people with diabetes are turning to underground donation networks when they cannot afford their insulin. Caps on insulin copays enacted in Colorado and 11 other states were designed to help. But the gaps between insulin costs and many patients’ financial realities are only widening amid the economic crisis of the COVID pandemic.
New Laws Keep Pandemic-Weary California at Forefront of Health Policy Innovation
Gov. Gavin Newsom approved many consequential health care bills by his bill-signing deadline Wednesday, including a ban on the sale of menthol and other flavored tobacco products, the creation of a state generic drug label and better coverage for mental health disorders.
Sky-High Drug Prices Driven by Pharma Profits, House Dems Charge
Democrats on the House Oversight Committee released a damning investigation Wednesday of drug company pricing tactics and profits, as two days of hearings with testimony from pharmaceutical industry CEOs begin.
Promises Kept? On Health Care, Trump’s Claims of ‘Monumental Steps’ Don’t Add Up
The president entered office seeking to overturn the Affordable Care Act, revamp Medicaid and drive down prescription drug prices, among other things. He’s hit some stone walls.
KHN’s ‘What the Health?’: ACA in Peril With Ginsburg’s Seat in Play
The death of Supreme Court Justice Ruth Bader Ginsburg is giving new life to the latest constitutional challenge to the Affordable Care Act. It also places anti-abortion activists on the cusp of a court majority large enough to ensure the rollback of the right to abortion and, possibly, some types of birth control. Meanwhile, Health and Human Services Secretary Alex Azar tries to centralize power at the sprawling department plagued by miscommunications and scandals. Anna Edney of Bloomberg News, Kimberly Leonard of Business Insider and Mary Ellen McIntire of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Plus, Rovner interviews KHN’s Sarah Jane Tribble about her new podcast, “Where It Hurts,” debuting Sept. 29.
It’s Not Just Insulin: Lawmakers Focus on Price of One Drug, While Others Rise Too
While insulin is the poster child for outrageous prescription costs, patients are paying ever more to treat depression, asthma, HIV, cholesterol and more. And the pandemic has overtaken efforts to force the issue in Congress.
¿Regalo para Florida? Trump aprobaría pronto importación de medicamentos de Canadá
A pesar de las objeciones de las farmacéuticas, se espera que la administración Trump finalice pronto el plan que permitiría a los estados importar medicamentos de venta bajo receta.
Election Gift for Florida? Trump Poised to Approve Drug Imports From Canada
The Trump administration is primed to approve a plan designed to help lower costs of some prescription drugs by allowing states to import them from Canada. The announcement could come before Election Day, and Florida appears to be in line to go first.
KHN’s ‘What the Health?’: It’s Scandal Week
President Donald Trump this week issued a prescription drug pricing order unlikely to lower drug prices, and he contradicted comments by his director of the Centers for Disease Control and Prevention on the need for mask-wearing and predictions for vaccine availability. Meanwhile, scandals erupted at the CDC, the Centers for Medicare & Medicaid Services and the Food and Drug Administration. And the number of people without health insurance grew in 2019, reported the Census Bureau, even while the economy soared. Alice Miranda Ollstein of Politico, Tami Luhby of CNN and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss this and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
California Rx: State May Dive Into Generic Drug Market
California could become the first state to develop its own line of generic drugs under a bill approved Monday by the legislature. The measure heads to Gov. Gavin Newsom for consideration.
Trump Again Claims He’s Bringing Down Drug Prices, But Details of How Are Skimpy
During his Monday speech at the Republican National Convention, President Donald Trump pointed to his two of his recent executive orders as likely to lead to big reductions in prescription drug costs.
KHN’s ‘What the Health?’: Democrats in Array (For Now)
In a highly produced, made-for-TV political convention, Democrats papered over their differences on a variety of issues, including health care, to show a unified front to defeat President Donald Trump in November. Meanwhile, COVID-19 continues to complicate efforts to get students back to school, and a federal judge blocks the Trump administration’s efforts to eliminate anti-discrimination protections for transgender people. Margot Sanger-Katz of The New York Times, Paige Winfield Cunningham of The Washington Post and Shefali Luthra of The 19th join KHN’s Julie Rovner to discuss this and more. Plus, for extra credit, the panelists recommend their favorite health stories of the week they think you should read, too.